Rein Therapeutics warned over Nasdaq $1 bid rule
Rein Therapeutics, Inc. (RNTX) reported receiving a Nasdaq delisting notice on August 21, 2026, because its common stock’s closing bid price was below $1.00 per share for the prior 30 consecutive trading days, violating Nasdaq Listing Rule 5550(a)(1).
Rhea-AI Filing Summary
Rein Therapeutics, Inc. (RNTX) reported receiving a Nasdaq delisting notice on August 21, 2026, because its common stock’s closing bid price was below $1.00 per share for the prior 30 consecutive trading days, violating Nasdaq Listing Rule 5550(a)(1).
Under Nasdaq Rule 5810(c)(3)(A), Rein Therapeutics has 180 days, until February 17, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If it does not regain compliance, it may seek an additional extension period if it meets other Nasdaq Capital Market initial listing standards, but there is no assurance that extra time will be granted. Failure to regain compliance would lead Nasdaq to begin suspension and delisting procedures for the company’s common stock.
Positive
- None.
Negative
- Rein Therapeutics received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price requirement under Rule 5550(a)(1).
- If the bid price is not restored to at least $1.00 for 10 consecutive business days by February 17, 2027, Nasdaq may initiate suspension and delisting procedures for RNTX.
- There is no assurance Nasdaq will grant additional time beyond the initial 180-day compliance period, increasing listing risk for the stock.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Minimum bid price requirement: $1.00 per share
Non-compliance observation period: 30 consecutive trading days
Initial compliance period length: 180 days
+2 more
5 metrics
Minimum bid price requirement
$1.00 per share
Required closing bid price under Nasdaq Listing Rule 5550(a)(1)
Non-compliance observation period
30 consecutive trading days
Period during which closing bid was below $1.00 leading to the delisting notice
Initial compliance period length
180 days
Time from August 21, 2026 notice until February 17, 2027 to regain compliance
Compliance measurement window
10 consecutive business days
Minimum span the bid price must be at or above $1.00 to regain compliance
Compliance deadline
February 17, 2027
End of the initial 180-day period to meet the minimum bid price requirement
Key Terms
Nasdaq Listing Rules, Rule 5550(a)(1), minimum bid price requirement, Rule 5810(c)(3)(A), +1 more
5 terms
Nasdaq Listing Rules regulatory
"below compliance with respect to the continued listing standard set forth in Rule 5550(a)(1) of the Nasdaq Listing Rules"
Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.
Rule 5550(a)(1) regulatory
"fallen below compliance with respect to the continued listing standard set forth in Rule 5550(a)(1)"
minimum bid price requirement financial
"to regain compliance with the minimum bid price requirement in Rule 5550(a)(1)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Rule 5810(c)(3)(A) regulatory
"Pursuant to the notice and Rule 5810(c)(3)(A) of the Nasdaq Listing Rules"
FAQ
Why did Rein Therapeutics (RNTX) receive a Nasdaq delisting notice?
Rein Therapeutics received a Nasdaq delisting notice because the closing bid price of its common stock was below $1.00 per share for the previous 30 consecutive trading days, causing non-compliance with Nasdaq Listing Rule 5550(a)(1) on minimum bid price.
How long does RNTX have to regain Nasdaq minimum bid price compliance?
Rein Therapeutics has 180 days from the August 21, 2026 notice, until February 17, 2027, to regain compliance by achieving a $1.00 or higher closing bid price for at least 10 consecutive business days under Nasdaq Rule 5810(c)(3)(A).
What happens to RNTX if it does not regain compliance by February 17, 2027?
If Rein Therapeutics does not regain compliance with Nasdaq Listing Rule 5550(a)(1) by February 17, 2027, Nasdaq may start suspension and delisting procedures for the company’s common stock from the Nasdaq Capital Market.
Can Rein Therapeutics (RNTX) get additional time from Nasdaq to fix its bid price?
Rein Therapeutics may qualify for additional time if it meets the Nasdaq Capital Market’s continued listing requirements for market value of publicly held shares and all other initial listing standards except bid price, and provides required undertakings, but no assurance of such extension is given.
What specific Nasdaq rules are cited in the RNTX delisting notice?
The notice cites Nasdaq Listing Rule 5550(a)(1), which sets the $1.00 minimum bid price requirement, and Rule 5810(c)(3)(A), which grants a 180-day period for Rein Therapeutics to regain compliance by achieving the required bid price for 10 consecutive business days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
